Literature DB >> 15735416

Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections.

Michael J Parnham1.   

Abstract

PURPOSE OF REVIEW: Several classes of antibiotics, particularly macrolides and to some extent quinolones, exert modulatory effects on inflammatory cells. With a growing number of experimental and clinical studies being performed, the relevance of the immunomodulatory actions of antibiotics to the therapy of respiratory infections is discussed in the light of recent reports. RECENT
FINDINGS: Antibiotics, particularly macrolides, exert both stimulatory and inhibitory effects on leukocytes. These effects seem to be related to the activation state of the leukocytes, facilitating bacterial killing as well as the resolution of local inflammation. In community-acquired pneumonia, this may account for the therapeutic benefit of macrolides, even when bacterial eradication is not complete. A variety of effects of macrolides on Pseudomonas aeruginosa, including the inhibition of biofilm matrix, contribute with immunomodulation to the improvement of respiratory function seen with macrolides in cystic fibrosis.
SUMMARY: Macrolides can facilitate the killing of microorganisms in acute respiratory infections through the stimulation of neutrophil activation. On long-term administration, anti-inflammatory, T helper type 1 lymphocyte-enhancing and biofilm-thinning actions, among others, make macrolides valid therapeutic options in chronic infectious/inflammatory disorders, even for infections with microorganisms that are not completely eradicated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735416     DOI: 10.1097/01.qco.0000160901.71813.fe

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  23 in total

1.  Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.

Authors:  Thomas P Lodise; Andrea Kwa; Leon Cosler; Reetu Gupta; Raymond P Smith
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

2.  Are macrolides now obligatory in severe community-acquired pneumonia?

Authors:  Grant W Waterer
Journal:  Intensive Care Med       Date:  2009-12-02       Impact factor: 17.440

Review 3.  The immune response and antibacterial therapy.

Authors:  Olachi Anuforom; Graham R Wallace; Laura V Piddock
Journal:  Med Microbiol Immunol       Date:  2014-09-05       Impact factor: 3.402

4.  Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin.

Authors:  Evan Zasowski; Jill M Butterfield; Louise-Ann McNutt; Jason Cohen; Leon Cosler; Manjunath P Pai; Joseph Gottwald; Wen Zhen Chen; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 5.  Azithromycin use in patients with cystic fibrosis.

Authors:  N Principi; F Blasi; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-17       Impact factor: 3.267

6.  Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction.

Authors:  Vittorio Magri; Emanuele Montanari; Višnja Škerk; Alemka Markotić; Emanuela Marras; Antonella Restelli; Kurt G Naber; Gianpaolo Perletti
Journal:  Asian J Androl       Date:  2011-07-18       Impact factor: 3.285

Review 7.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

8.  Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes.

Authors:  Wendy I Sligl; Holly Hoang; Dean T Eurich; Atul Malhotra; Thomas J Marrie; Sumit R Majumdar
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

9.  Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma.

Authors:  Ute I Scholl; Laura Abriola; Chengbiao Zhang; Esther N Reimer; Mark Plummer; Barbara I Kazmierczak; Junhui Zhang; Denton Hoyer; Jane S Merkel; Wenhui Wang; Richard P Lifton
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

10.  Azithromycin use and outcomes in severe sepsis patients with and without pneumonia.

Authors:  Majid Afshar; Clayton L Foster; Jennifer E Layden; Ellen L Burnham
Journal:  J Crit Care       Date:  2015-12-21       Impact factor: 3.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.